Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trial
MedicinaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Human vaccines & immunotherapeutics
- Publicado em
- 17 jun 2022
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trial
Jinhua Chen, Pengfei Jin, Xiaoqi Chen, Qunying Mao, Fanyue Meng, Xinguo Li, Wei Chen, Meizhi Du, Fan Gao, Pei Liu et al.
Descritores MeSH
- Enterovirus A, Human
- Enterovirus
- Double-Blind Method
- Humans
- Vaccines, Inactivated
- Antibodies, Viral
- Antibodies, Neutralizing
- Child
Estudos relacionados
- Immunogenicity and safety of an inactivated enterovirus 71 vaccine co-administered with measles-mumps-rubella vaccine and live-attenuated Japanese encephalitis vaccine: a phase 4, single-center, randomized controlled trial
- Long-term protection of an inactivated enterovirus type 71 vaccine against hand, foot, and mouth diseases in children: a modelling study
- Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial
- Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial